Ostatní
Návod 
Kamada Ltd.
KMDA
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.4B
Obrat
0B
Zisk
0B
Aktiva
0B
Dluh
0B
ROE
8%
ROA
5%
PE
26
PS
3
Cena 1R
6-9
⌀ Cena
7.04
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
04-03-2026
Poslední dividenda
17-03-2025
Profil
Společnost Kamada Ltd. poskytuje léčbu proteinů odvozených z plazmy. Působí ve dvou segmentech, Proprietary Products a Distribution. Společnost nabízí KAMRAB/KEDRAB pro profylaxi vztekliny; CYTOGAM pro profylaxi cytomegaloviru u transplantace ledvin, plic, jater, slinivky břišní, srdce a srdce/plic; WINRHO SDF pro imunitní trombocytopenickou purpuru a potlačení rhesus izoimunizace; HEPAGAM B pro prevenci rekurence hepatitidy B pro transplantaci jater a postexpoziční profylaxi; VARIZIG pro postexpoziční profylaxi varicely; a GLASSIA pro intravenózní AATD. Poskytuje také KamRho (D) IM pro profylaxi hemolytického onemocnění novorozenců, KamRho (D) IV pro imunitní termobocytopunickou purpuru a antisérum proti kousnutí hada k léčbě kousnutí vipera palaestinae a echis coloratus. Kromě toho společnost distribuuje BRAMITOB k léčbě chronické plicní infekce; FOSTER k léčbě astmatu; PROVOCHOLINE k diagnostice hyperaktivity bronchiálních dýchacích cest; AEROBIKA, zařízení OPEP; RUPAFIN k léčbě alergické rýmy a urtikárie; IVIG k léčbě onemocnění souvisejících s imunodeficiencí; VARITECT k léčbě herpes neštovic a zoster; ZUTECTRA a HEPATECT CP k léčbě hepatitidy B; MEGALOTECT CP k léčbě viru cytomegaloviru; RUCONEST k léčbě záchvatů angioedému; injekce heparinu sodného k léčbě trombinu Mbo-embolické poruchy a profylaxe hluboké žilní trombózy a tromboembolických příhod; ALBUMIN pro krevní plazmu; Faktor VIII pro hemofilii typu A a faktor IX pro hemofilii typu B. Dále nabízí IXIARO pro japonskou encefalitidu; VIVOTIF pro Salmonella Typhi; PROCYSBI pro nefropatickou cystinózu; LAMZEDE pro alfa-mannosidózu; a ELIGARD pro karcinom prostaty. Společnost prodává své výrobky prostřednictvím strategických partnerů ve Spojených státech, stejně jako prostřednictvím distributorů v mezinárodním měřítku. Společnost Kamada Ltd. má strategická partnerství se společnostmi Takeda Pharmaceuticals Company Limited, PARI GmbH a Kedrion Biopharma. Společnost byla založena v roce 1990 a sídlí v izraelském Rehovotu.
Sektor
Healthcare
Odvětví
Drug Manufacturers - Specialty & Generic
Počet zaměstnanců
420
Založení
2013-05-31
Podobné společnosti
$ 7.04
+ $ 0.48
$ 1.61
+ $ 0.03
$ 3.15
- $ 0.03
$ 28.26
+ $ 0.66
$ 33.43
+ $ 0.24
$ 17.50
+ $ 0.26
$ 24.82
- $ 0.04
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 181.4 | 195.3 | 161.0 | 142.5 | 129.3 | 103.6 | 133.2 | 127.2 | 114.5 | 102.8 | 77.5 | 70.1 | 71.9 | 70.6 | 72.7 | 55.9 | 36.3 | |
| Cost of Revenues | 104.6 | 117.1 | 91.0 | 87.0 | 82.6 | 73.3 | 85.7 | 77.5 | 73.0 | 70.7 | 55.8 | 54.1 | 56.3 | 44.2 | 50.0 | 40.2 | 30.2 | |
| Gross Profit | 76.8 | 78.3 | 70.0 | 55.5 | 46.7 | 30.3 | 47.6 | 49.7 | 41.5 | 32.1 | 21.7 | 16.0 | 15.6 | 26.4 | 22.7 | 15.7 | 6.1 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 45.6 | 47.0 | 44.8 | 44.0 | 39.0 | 41.7 | 42.5 | 37.7 | 38.4 | 37.9 | |
| Cost of Revenues | 28.3 | 27.2 | 25.8 | 23.3 | 22.0 | 24.5 | 23.5 | 21.0 | 23.2 | 23.1 | |
| Gross Profit | 17.3 | 19.8 | 18.9 | 20.7 | 17.0 | 17.2 | 19.0 | 16.8 | 15.2 | 14.8 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 13.9 | 13.2 | 11.4 | 13.6 | 13.1 | 9.7 | 12.0 | 16.2 | 16.5 | 16.0 | 12.7 | 11.8 | 11.0 | 9.8 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 27.4 | 28.1 | 18.9 | 14.7 | 13.6 | 12.2 | 12.7 | 10.9 | 10.9 | 10.5 | 10.0 | 6.3 | 7.0 | 7.0 | |
| Depreciation & Amortization | 15.0 | 16.1 | 13.8 | 11.5 | 12.2 | 5.6 | 5.9 | 5.7 | 3.7 | 3.5 | 3.5 | 3.2 | 2.8 | 3.0 | 3.0 | 2.9 | 2.8 | |
| Total Operating Expenses | 50.5 | 49.9 | 49.9 | 45.4 | 42.2 | 31.0 | 28.3 | 27.0 | 22.2 | 24.6 | 27.1 | 27.4 | 26.5 | 22.7 | 18.5 | 18.0 | 16.8 | |
| Operating Income | 26.3 | 28.4 | 20.1 | 10.1 | -1.6 | -0.4 | 19.2 | 22.8 | 19.3 | 7.4 | -5.8 | -11.4 | -10.9 | 3.7 | 4.2 | -2.3 | -10.7 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.4 | 3.2 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.8 | 7.4 | ||
| Depreciation & Amortization | 3.9 | 3.8 | 3.7 | 3.6 | 4.1 | 3.2 | 3.2 | 3.2 | 3.4 | 3.1 | ||
| Total Operating Expenses | 13.7 | 11.9 | 11.9 | 13.0 | 12.0 | 11.9 | 13.3 | 12.7 | 12.2 | 10.4 | ||
| Operating Income | 3.6 | 7.8 | 7.1 | 7.8 | 5.1 | 5.3 | 5.6 | 4.0 | 2.9 | 4.4 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 1.9 | 2.1 | 2.1 | 0.6 | 0.1 | 0.3 | 1.0 | 1.1 | 0.8 | 0.5 | 0.5 | 0.5 | 1.6 | 0.3 | 0.6 | 2.6 | 0.0 | |
| Interest Expense | 0.9 | 0.9 | 0.7 | 1.3 | 0.9 | 1.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.1 | 0.9 | 3.1 | 3.2 | 3.4 | 3.8 | -4.4 | |
| Other Expense | -2.7 | -3.0 | -6.7 | -1.6 | -0.6 | -1.5 | -0.7 | 0.2 | 0.6 | -0.6 | 0.1 | 0.6 | -0.2 | -0.4 | -0.7 | -3.8 | -4.4 | |
| IBT | 23.6 | 25.4 | 13.3 | 8.4 | -2.3 | -1.9 | 18.6 | 23.0 | 20.3 | 7.2 | -5.0 | -11.3 | -12.6 | 0.5 | 0.8 | -3.5 | -15.2 | |
| Income Tax Expense | 3.3 | 3.5 | -1.1 | 0.1 | 0.1 | 0.3 | 1.4 | 0.7 | -2.0 | 0.3 | 1.7 | -0.2 | 0.1 | 0.0 | 0.5 | 3.8 | 4.4 | |
| Net Income | 20.3 | 21.9 | 14.5 | 8.3 | -2.3 | -2.2 | 17.1 | 22.3 | 22.3 | 6.9 | -6.7 | -11.3 | -12.6 | 0.4 | 0.3 | -3.5 | -15.2 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.5 | 0.5 | 0.5 | 0.5 | 0.7 | 0.6 | 0.5 | 0.3 | 1.8 | 0.1 | ||
| Interest Expense | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.0 | 0.4 | ||
| Other Expense | 1.2 | -1.4 | -1.3 | -1.2 | -2.6 | -1.3 | -1.2 | -1.6 | 2.1 | -1.1 | ||
| IBT | 4.8 | 6.4 | 5.8 | 6.6 | 2.5 | 3.9 | 4.5 | 2.4 | 5.3 | 3.3 | ||
| Income Tax Expense | 1.2 | 1.1 | -1.6 | 2.6 | -1.3 | 0.1 | 0.1 | 0.1 | 0.0 | 0.1 | ||
| Net Income | 3.6 | 5.3 | 7.4 | 4.0 | 3.8 | 3.9 | 4.4 | 2.4 | 5.1 | 3.2 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.17 | $-0.05 | $-0.05 | $0.39 | $0.55 | $0.55 | $0.18 | $-0.18 | $-0.31 | $-0.35 | $0.01 | $0.01 | $-0.13 | $-0.61 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.15 | $-0.05 | $-0.05 | $0.38 | $0.55 | $0.55 | $0.18 | $-0.18 | $-0.31 | $-0.35 | $0.01 | $0.01 | $-0.13 | $-0.61 | |
| Shares Outstanding | 57.7 | 57.6 | 57.5 | 48.8 | 44.6 | 44.8 | 43.9 | 40.3 | 40.5 | 38.0 | 36.4 | 36.2 | 36.0 | 32.7 | 28.1 | 27.6 | 25.1 | |
| Diluted Shares Outstanding | 61.7 | 58.3 | 57.8 | 53.7 | 44.6 | 44.9 | 45.1 | 40.6 | 40.5 | 38.0 | 36.4 | 36.2 | 36.0 | 33.4 | 28.7 | 27.7 | 25.1 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.09 | $0.07 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.09 | $0.06 | ||
| Shares Outstanding | 57.7 | 58.8 | 56.7 | 56.6 | 54.4 | 55.2 | 55.3 | 57.5 | 57.5 | 46.0 | ||
| Diluted Shares Outstanding | 61.7 | 58.8 | 56.7 | 56.6 | 54.4 | 55.2 | 55.3 | 57.5 | 57.5 | 53.7 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 56.4 | 78.4 | 55.6 | 34.3 | 18.6 | 70.2 | 42.7 | 18.1 | 12.7 | 10.0 | 5.0 | 14.5 | 59.1 | 16.9 | 24.5 | 25.7 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 39.1 | 31.2 | 32.5 | 30.3 | 18.7 | 23.3 | 37.4 | 15.1 | 16.9 | 16.9 | 20.4 | |
| Total Cash & ST Investments | 56.4 | 78.4 | 55.6 | 34.3 | 18.6 | 109.3 | 73.9 | 50.6 | 43.0 | 28.6 | 28.3 | 51.9 | 74.2 | 33.8 | 41.3 | 46.1 | |
| Accounts Receivable | 31.1 | 23.2 | 21.3 | 36.0 | 44.0 | 26.6 | 26.5 | 31.0 | 32.8 | 22.9 | 26.0 | 20.4 | 21.6 | 14.3 | 8.3 | 14.8 | |
| Inventory | 78.5 | 78.8 | 88.5 | 68.8 | 67.4 | 42.0 | 43.2 | 29.3 | 21.1 | 25.6 | 26.3 | 25.4 | 21.9 | 20.7 | 15.4 | 10.6 | |
| Other Current Assets | 0.0 | 3.9 | 4.6 | 3.9 | 8.9 | 4.5 | 3.3 | 1.1 | 0.8 | 1.1 | 0.9 | 1.1 | 1.4 | 1.1 | 2.3 | 0.0 | |
| Total Current Assets | 165.9 | 184.3 | 170.0 | 139.0 | 130.0 | 177.9 | 143.6 | 110.9 | 96.9 | 77.1 | 80.6 | 97.7 | 117.7 | 69.8 | 67.3 | 71.4 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 72.0 | 66.0 | 76.3 | 78.4 | 72.0 | 56.5 | 48.2 | 55.2 | 52.6 | 21.8 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 72.0 | 66.0 | 76.3 | 78.4 | 72.0 | 56.5 | 48.2 | 55.2 | 52.6 | 21.8 | |
| Accounts Receivable | 35.3 | 35.2 | 33.9 | 23.2 | 20.9 | 26.2 | 18.9 | 19.9 | 25.1 | 24.6 | |
| Inventory | 85.4 | 82.1 | 78.4 | 78.8 | 71.6 | 78.7 | 84.3 | 87.7 | 73.8 | 80.2 | |
| Other Current Assets | 0.0 | 0.0 | 0.0 | 3.9 | 0.0 | 4.9 | 6.4 | 6.0 | 0.0 | 0.0 | |
| Total Current Assets | 192.7 | 183.3 | 188.5 | 184.3 | 164.4 | 166.4 | 157.8 | 168.6 | 153.2 | 129.7 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 39.4 | 45.9 | 36.0 | 28.7 | 29.4 | 29.1 | 28.6 | 25.0 | 25.2 | 22.2 | 21.3 | 21.8 | 21.4 | 18.8 | 17.5 | 19.7 | |
| Goodwill | 0.0 | 30.3 | 30.3 | 30.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 101.9 | 109.6 | 116.7 | 153.6 | 1.5 | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 8.2 | 0.0 | 8.4 | 0.0 | 0.0 | 0.0 | -0.3 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 136.4 | 9.4 | 0.6 | 7.6 | 5.6 | 2.1 | 0.4 | 0.2 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.3 | 0.6 | 0.3 | |
| Total Long-Term Assets | 184.0 | 187.9 | 184.9 | 183.4 | 188.6 | 32.8 | 30.2 | 27.2 | 25.2 | 22.6 | 21.4 | 21.9 | 21.7 | 19.3 | 18.1 | 20.1 | |
| Total Assets | 349.9 | 372.3 | 354.9 | 322.4 | 318.7 | 210.7 | 173.8 | 138.1 | 122.1 | 99.7 | 102.0 | 119.6 | 139.4 | 89.1 | 85.4 | 91.5 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 47.3 | 47.1 | 46.9 | 45.9 | 43.6 | 39.5 | 38.4 | 35.7 | 32.9 | 32.5 | |
| Goodwill | 30.3 | 30.3 | 30.3 | 30.3 | 0.0 | 0.0 | 0.0 | 30.1 | 0.0 | 0.0 | |
| Intangible Assets | 99.2 | 99.6 | 101.4 | 101.9 | 135.0 | 136.8 | 138.6 | 109.6 | 142.5 | 144.0 | |
| Long-Term Investments | 0.0 | 7.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 8.4 | 8.5 | 8.3 | |
| Other Long-Term Assets | 7.7 | 0.0 | 7.9 | 9.4 | 8.2 | 8.3 | 8.4 | 0.5 | 8.5 | 8.3 | |
| Total Long-Term Assets | 184.5 | 184.9 | 186.6 | 187.9 | 186.8 | 184.6 | 185.4 | 183.4 | 183.9 | 184.7 | |
| Total Assets | 377.2 | 368.2 | 375.1 | 372.3 | 351.2 | 351.0 | 343.2 | 352.0 | 337.1 | 314.4 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 19.5 | 27.7 | 24.8 | 32.9 | 25.1 | 16.1 | 24.8 | 17.3 | 18.0 | 16.3 | 16.9 | 16.5 | 14.1 | 12.0 | 12.6 | 19.0 | |
| Short-Term Debt | 1.5 | 1.6 | 1.4 | 5.5 | 3.8 | 1.3 | 1.5 | 0.6 | 0.6 | 0.4 | 0.0 | 7.5 | 8.7 | 5.4 | 0.0 | 0.0 | |
| Other Current Liabilities | 19.8 | 19.9 | 23.1 | 37.3 | 25.1 | 5.5 | 5.8 | 5.3 | 5.8 | 5.6 | 4.1 | 4.0 | 4.3 | 3.6 | 3.1 | 0.9 | |
| Current Liabilities | 40.8 | 49.4 | 49.6 | 75.7 | 54.1 | 25.0 | 32.7 | 23.6 | 29.4 | 27.2 | 22.9 | 30.9 | 32.6 | 29.2 | 23.0 | 19.9 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 24.9 | 25.1 | 24.9 | 27.7 | 14.8 | 19.5 | 16.5 | 24.8 | 12.8 | 28.0 | |
| Short-Term Debt | 1.9 | 1.9 | 1.8 | 1.6 | 1.6 | 1.5 | 1.5 | 1.4 | 1.1 | 5.5 | |
| Other Current Liabilities | 20.0 | 18.7 | 30.2 | 19.9 | 17.6 | 19.9 | 19.2 | 23.0 | 23.3 | 32.3 | |
| Current Liabilities | 47.8 | 45.8 | 57.0 | 49.4 | 34.0 | 40.9 | 37.2 | 49.2 | 37.3 | 65.8 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 7.1 | 9.4 | 7.4 | 15.1 | 20.6 | 3.6 | 4.2 | 0.7 | 1.4 | 1.4 | 0.2 | 0.0 | 7.5 | 18.7 | 22.5 | 23.2 | |
| Capital Leases | 7.0 | 11.1 | 8.8 | 3.2 | 4.3 | 4.7 | 5.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 0.0 | 0.0 | 16.9 | 21.1 | 16.5 | 13.0 | 0.0 | 12.0 | -5.3 | -18.7 | -24.4 | |
| Total Liabilities | 99.6 | 112.8 | 110.9 | 146.4 | 141.8 | 32.0 | 38.5 | 25.7 | 32.6 | 33.0 | 29.5 | 38.6 | 49.4 | 60.7 | 62.8 | 65.0 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 9.6 | 9.5 | 9.3 | 9.4 | 9.6 | 7.1 | 7.3 | 7.4 | 4.7 | 15.7 | |
| Capital Leases | 11.5 | 11.4 | 11.1 | 11.1 | 11.2 | 8.6 | 8.7 | 7.4 | 5.9 | 6.0 | |
| Def. Tax Liability | 1.7 | 0.7 | 2.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 112.0 | 108.2 | 123.1 | 112.8 | 95.9 | 99.9 | 96.7 | 110.0 | 98.7 | 137.6 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 15.0 | 15.0 | 14.9 | 11.7 | 11.7 | 11.7 | 10.4 | 10.4 | 10.4 | 9.3 | 9.3 | 9.2 | 9.2 | 7.2 | 7.7 | 8.2 | |
| Retained Earnings | -33.3 | -25.7 | -40.2 | -48.5 | -46.2 | -43.9 | -61.1 | -83.0 | -104.6 | -111.5 | -104.7 | -92.9 | -80.2 | -80.7 | -88.9 | -91.6 | |
| Comprehensive Income | 3.2 | -3.1 | -3.1 | -3.2 | -3.6 | -3.5 | -3.7 | -3.5 | -3.8 | -3.6 | -3.5 | -3.7 | 1.7 | -3.4 | 4.9 | -22.2 | |
| Total Common Equity | 250.4 | 259.5 | 244.0 | 176.0 | 176.8 | 178.6 | 135.3 | 112.4 | 89.5 | 66.7 | 72.5 | 81.0 | 90.0 | 28.4 | 22.7 | 26.5 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 15.1 | 15.1 | 15.1 | 15.0 | 15.0 | 15.0 | 15.0 | 14.9 | 15.0 | 11.7 | |
| Retained Earnings | -20.6 | -25.9 | -33.3 | -25.7 | -29.5 | -33.4 | -37.8 | -39.9 | -45.3 | -48.5 | |
| Comprehensive Income | -2.8 | -2.7 | -3.2 | -3.1 | -3.2 | 3.2 | 3.1 | 3.3 | -3.3 | -3.1 | |
| Total Common Equity | 265.2 | 260.0 | 252.0 | 259.5 | 255.3 | 251.2 | 246.5 | 242.0 | 238.4 | 176.8 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 8.5 | 11.1 | 8.8 | 20.6 | 24.4 | 4.9 | 5.7 | 1.3 | 2.0 | 1.8 | 0.2 | 7.5 | 16.2 | 24.1 | 22.5 | 23.2 | |
| Book Value | 250.4 | 259.5 | 244.0 | 176.0 | 176.8 | 178.6 | 135.3 | 112.4 | 89.5 | 66.7 | 72.5 | 81.0 | 90.0 | 28.4 | 22.7 | 26.5 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 265.2 | 260.0 | 252.0 | 259.5 | 255.3 | 251.2 | 246.5 | 242.0 | 238.4 | 176.8 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 15.3 | 21.9 | 14.5 | 8.4 | -2.3 | -2.2 | 17.1 | 22.3 | 22.3 | 6.9 | -6.7 | -11.3 | -12.6 | 0.4 | 0.3 | -3.5 | -15.2 | |
| Depreciation & Amortization | 12.9 | 16.1 | 13.8 | 12.9 | 12.2 | 5.6 | 4.9 | 4.5 | 3.7 | 3.5 | 3.5 | 3.2 | 2.8 | 3.0 | 3.0 | 2.9 | 2.8 | |
| Stock-Based Compensation | 1.2 | 0.0 | 0.9 | 1.3 | 1.2 | 0.5 | 1.0 | 1.2 | 0.9 | 0.5 | 1.1 | 1.9 | 3.8 | 1.3 | 1.3 | 1.0 | 1.8 | |
| Change Working Capital | -10.7 | -19.1 | 11.4 | -18.2 | 11.6 | -14.4 | -7.1 | -1.7 | -14.1 | -7.9 | 3.9 | -8.4 | -4.9 | -10.7 | -14.3 | 1.4 | 18.6 | |
| Change In Accounts Receivable | -4.3 | -5.9 | -0.9 | 6.8 | 7.6 | -12.9 | 1.3 | 5.1 | 2.3 | -10.0 | 3.5 | -5.6 | -1.3 | -3.4 | -6.7 | 5.4 | -8.6 | |
| Change In Accounts Payable | -8.8 | -7.4 | 1.2 | -9.0 | 7.1 | 7.9 | -9.6 | 6.3 | -1.1 | -0.6 | -2.7 | 0.9 | 3.3 | 1.6 | -0.2 | 1.2 | 6.2 | |
| Change In Inventories | 1.1 | -6.6 | 9.7 | -20.0 | -1.4 | -2.4 | 1.2 | -13.9 | -8.2 | 4.5 | 0.7 | -0.9 | -3.5 | -1.2 | -4.9 | -6.1 | -1.9 | |
| Other Non-cash Items | 15.8 | 8.7 | 8.2 | -0.3 | 5.9 | 1.3 | 1.8 | 0.6 | -0.4 | 0.7 | -1.6 | -0.2 | 1.0 | 2.1 | 0.9 | 1.2 | 4.4 | |
| Cash from Operations | 20.1 | 0.0 | 0.0 | 4.3 | 28.6 | -8.8 | 19.1 | 27.6 | 10.5 | 3.9 | 1.9 | -14.0 | -9.9 | -3.9 | -8.3 | 0.9 | 10.6 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 3.6 | 5.3 | 7.4 | 4.0 | 3.8 | 3.9 | 4.4 | 2.4 | 5.3 | 3.2 | |
| Depreciation & Amortization | 3.9 | 3.8 | 3.7 | 3.6 | 4.1 | 3.2 | 3.2 | 3.2 | 3.4 | 3.2 | |
| Stock-Based Compensation | 0.0 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.3 | |
| Change Working Capital | -0.2 | -1.6 | -3.2 | -12.4 | 0.5 | 13.0 | 4.6 | -6.6 | -2.1 | -6.4 | |
| Change In Accounts Receivable | 2.6 | -0.4 | -0.2 | -7.2 | -5.6 | 10.5 | -5.8 | 0.1 | 2.0 | -0.6 | |
| Change In Accounts Payable | -3.6 | 0.6 | -0.4 | -3.7 | 12.0 | -5.7 | 3.7 | -8.8 | 9.6 | -13.2 | |
| Change In Inventories | 0.6 | -3.3 | -3.7 | 0.5 | -7.3 | 7.2 | 5.6 | 4.1 | -15.0 | 6.4 | |
| Other Non-cash Items | 0.5 | 1.7 | 1.6 | 1.5 | 3.2 | 1.8 | 1.4 | 1.7 | -2.5 | 0.6 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.5 | 0.9 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -9.4 | -10.7 | -10.7 | -5.9 | -3.8 | -3.7 | -5.5 | -2.3 | -2.9 | -4.4 | -2.6 | -2.7 | -3.1 | -5.6 | -4.6 | -1.9 | -3.8 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -96.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -19.7 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 39.1 | -7.6 | 1.7 | -2.3 | -11.4 | 4.3 | 14.0 | -23.7 | 1.7 | 2.2 | 0.8 | 0.2 | |
| Cash from Investing | -9.4 | 0.0 | 0.0 | -5.8 | -3.8 | -61.1 | -13.1 | -0.6 | -5.2 | -15.9 | 1.6 | 11.3 | -26.8 | -3.9 | -2.4 | -1.1 | -23.3 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -2.9 | -3.6 | -2.0 | -1.5 | -2.9 | -2.1 | -3.0 | -2.7 | -2.1 | -1.7 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.1 | -1.7 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -27.8 | 0.0 | 0.0 | -18.3 | -9.4 | -1.4 | -1.6 | -1.5 | -0.6 | -0.5 | -0.2 | -7.8 | -7.7 | -4.3 | 0.0 | -0.9 | -0.1 | |
| Debt Issued | 15.1 | 11.1 | 2.2 | 6.5 | 5.6 | 20.8 | 0.8 | 6.0 | -0.1 | 0.7 | 1.8 | 0.5 | -1.0 | -3.6 | 1.6 | 0.2 | 23.2 | |
| Issuance of Common Stock | 59.2 | 0.0 | 0.0 | 59.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | -19.0 | 0.0 | 0.0 | -17.3 | 0.0 | 20.0 | 25.0 | 0.0 | 0.0 | 15.9 | 1.7 | 1.5 | 0.1 | 53.5 | 3.0 | 0.5 | 7.6 | |
| Cash from Financing | 23.5 | 0.0 | 0.0 | 22.7 | -9.3 | 18.6 | 23.4 | -1.5 | -0.6 | 15.3 | 1.5 | -6.4 | -7.6 | 49.2 | 3.0 | -0.4 | 7.6 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.3 | -15.4 | |
| Debt Issued | 11.5 | 0.1 | 0.3 | 0.0 | -0.1 | 2.6 | -0.2 | 0.0 | 3.2 | 0.1 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 58.2 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | -11.5 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 31.3 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 34.8 | -3.0 | 22.8 | 21.4 | 15.7 | -51.3 | 27.5 | 24.6 | 5.4 | 2.7 | 4.9 | -9.5 | -44.6 | 42.2 | -7.5 | 0.5 | -6.7 | |
| Closing Cash Balance | 56.4 | 75.5 | 78.4 | 55.6 | 34.3 | 18.9 | 70.2 | 42.7 | 18.1 | 12.7 | 10.0 | 5.0 | 14.5 | 59.1 | 16.9 | 24.5 | 25.7 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 3.7 | 6.0 | -10.3 | -2.2 | 6.4 | 15.5 | 8.4 | -7.4 | 2.8 | 30.8 | |
| Closing Cash Balance | 75.5 | 72.0 | 66.0 | 76.3 | 78.4 | 72.0 | 56.5 | 48.2 | 55.2 | 52.6 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 10.6 | 16.9 | 36.9 | -1.5 | 24.8 | -12.5 | 13.6 | 25.3 | 7.7 | -0.6 | -0.7 | -16.7 | -13.0 | -9.5 | -12.9 | -0.9 | 6.8 | |
| Real Free Cash Flow | 9.5 | 16.9 | 36.0 | -2.8 | 23.6 | -13.1 | 12.6 | 24.1 | 6.7 | -1.0 | -1.8 | -18.6 | -16.7 | -10.8 | -14.1 | -1.9 | 5.0 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 5.0 | 6.8 | 6.0 | -2.0 | 7.5 | 20.1 | 11.0 | -1.7 | 2.4 | -0.8 | |
| Real Free Cash Flow | 5.0 | 6.7 | 5.9 | -2.2 | 7.3 | 19.9 | 10.7 | -1.9 | 2.0 | -1.1 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 25.9 | 19.7 | 2356.8 |
| P/S | 2.9 | 2.6 | 70.5 |
| P/B | 2 | 2.3 | 2015.4 |
| P/FCF | 34 | -11.2 | 7573.5 |
| Market cap | $0.4 | $0.3 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 3 % | 5.5 % | 0 % |
| Debt to Income | 56.6 % | 43.3 % | 0 % |
| Debt to Free cash flow | 74.4 % | -175.9 % | 0 % |
| Interest expense percentage | 3.3 % | 18.3 % | 26.2 % |
| Current ratio | 4 | 3.8 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 7.6 % | 1.5 % | 0 % |
| ROA | 5.4 % | 1.6 % | 0 % |
| CapEx to Revenue | 5.7 % | 4.5 % | 6 % |
| RaD to Revenue | 0 % | 14 % | 0 % |
| ROEM | 453,453.3 | 240834.8 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 43.8 % | 33 % | 74.8 % |
| Operating margin | 15.9 % | 3.3 % | 35 % |
| Net margin | 11.7 % | 1.5 % | 34.1 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 1.1 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 58.8 mil | 41.3 mil |
| Employee count | 0.4 tis | 0.4 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
